37.89
Schlusskurs vom Vortag:
$37.03
Offen:
$36.87
24-Stunden-Volumen:
298.84K
Relative Volume:
0.61
Marktkapitalisierung:
$1.65B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-270.64
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
-0.60%
1M Leistung:
+2.13%
6M Leistung:
+83.13%
1J Leistung:
+42.28%
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Vergleichen Sie KNSA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KNSA
Kiniksa Pharmaceuticals International Plc
|
37.89 | 2.74B | 384.10M | -9.07M | 11.10M | -0.14 |
![]()
ZTS
Zoetis Inc
|
143.46 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.80 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.17 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
433.61 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-09-29 | Eingeleitet | TD Cowen | Buy |
2025-03-13 | Eingeleitet | Citigroup | Buy |
2024-09-13 | Eingeleitet | Jefferies | Buy |
2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
2020-06-29 | Bestätigt | BofA Securities | Buy |
2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
2019-03-11 | Eingeleitet | Barclays | Overweight |
2018-12-12 | Bestätigt | Wedbush | Outperform |
2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet - sharewise.com
Wedbush Issues Optimistic Forecast for KNSA Earnings - MarketBeat
KNSA: Wedbush Maintains Outperform Rating, Raises Price Target t - GuruFocus
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals International to $44 From $38, Keeps Outperform Rating - MarketScreener
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 1-Year HighStill a Buy? - MarketBeat
Looking at the Narrative for Kiniksa Pharmaceuticals as Analyst Optimism Grows with Arcalyst Momentum - Yahoo Finance
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Robeco Institutional Asset Management B.V. Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to "Hold" at Zacks Research - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Stock Position Reduced by Knights of Columbus Asset Advisors LLC - MarketBeat
Wealth Enhancement Advisory Services LLC Has $430,000 Stake in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Here's What Could Help Kiniksa Pharmaceuticals International, plc (KNSA) Maintain Its Recent Price Strength - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of USD 39.12 - Markets Mojo
AMI Asset Management Corp Sells 34,547 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 42,000 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals Hits New 52-Week High of $38.97 - Markets Mojo
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Now Covered by TD Cowen - Defense World
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 52-Week HighWhat's Next? - MarketBeat
KNSA: TD Cowen Initiates Coverage with 'Buy' Rating and $60 PT | - GuruFocus
TD Cowen Initiates Kiniksa Pharmaceuticals International at Buy With $60 Price Target - MarketScreener
Risk vs reward if holding onto Kiniksa Pharmaceuticals Ltd.Quarterly Investment Review & Long-Term Safe Return Strategies - newser.com
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $45.00 Price Target at Wells Fargo & Company - Defense World
Voya Investment Management LLC Buys 10,878 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program - The Globe and Mail
Wells Fargo Raises KNSA Price Target to $45, Maintains Overweigh - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience - sharewise.com
Strs Ohio Acquires Shares of 26,800 Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Goldman Sachs Group Inc. Has $3.47 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Pallas Capital Advisors LLC Buys New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
10,700 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Acquired by Toth Financial Advisory Corp - MarketBeat
Strs Ohio Purchases Shares of 26,800 Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells 16,400 Shares of Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Short Interest Update - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by Rhumbline Advisers - Defense World
Kiniksa Pharmaceuticals International, plc (KNSA) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $41.17 Average PT from Analysts - MarketBeat
What high frequency data says about Kiniksa Pharmaceuticals Ltd.Market Weekly Review & Safe Capital Growth Tips - newser.com
Fred Alger Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Holdings Raised by AQR Capital Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Acadian Asset Management LLC - MarketBeat
Using fundamentals and technicals on Kiniksa Pharmaceuticals Ltd.July 2025 Decliners & Long-Term Growth Plans - newser.com
Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN
Backtesting results for Kiniksa Pharmaceuticals Ltd. trading strategiesRisk Management & Free High Accuracy Swing Entry Alerts - newser.com
Exploring High Growth Tech Stocks in the US Market September 2025 - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells 3,523 Shares of Stock - MarketBeat
Eben Tessari Sells 13,389 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):